OLMETN-40

Description

OLMETN-40 contains Olmesartan Medoxomil 40 mg in tablet form. Olmesartan medoxomil belongs to the angiotensin II receptor blocker (ARB) class and helps lower high blood pressure in adults with hypertension. It blocks the action of angiotensin II at the AT1 receptor. As a result, blood vessels relax and blood pressure can decrease when a healthcare professional prescribes the medicine appropriately.

For related cardiovascular and antihypertensive formulations, explore the Medhexa Pharma product range for pharmaceutical products and business enquiries.

Therapeutic Segment

Cardiovascular Care | Antihypertensive Therapy | Blood Pressure Management | ARBs | Hypertension Management

Uses of OLMETN-40

OLMETN-40 may be prescribed as part of a treatment plan for:

• High blood pressure (hypertension)
• Long-term blood pressure management
• Patients who require ARB therapy
• Blood pressure control when lifestyle measures alone do not provide adequate control
• Patients who need additional antihypertensive treatment according to their clinical condition

Olmesartan medoxomil helps reduce the effects of angiotensin II on blood vessels. Therefore, it can support blood pressure control when a healthcare professional considers ARB therapy appropriate.

Key Benefits of OLMETN-40

• Blood Pressure Management: Olmesartan medoxomil helps lower elevated blood pressure.
• ARB Therapy: Olmesartan belongs to the angiotensin II receptor blocker class.
• 40 mg Strength: Each tablet contains Olmesartan Medoxomil 40 mg.
• Supports Blood Vessel Relaxation: The medicine blocks angiotensin II from producing its blood-vessel-narrowing effect.
• Convenient Oral Form: The tablet provides a convenient oral dosage form for prescribed treatment.
• Long-Term Hypertension Support: Regular treatment can help maintain blood pressure control when used as directed.

How OLMETN-40 Works

Olmesartan medoxomil acts as a prodrug that converts to olmesartan during absorption. Olmesartan then selectively blocks angiotensin II from binding to the AT1 receptor.

Normally, angiotensin II causes blood vessels to constrict and contributes to increased blood pressure. However, olmesartan blocks this action. Consequently, the blood vessels relax, vascular resistance decreases and blood pressure can fall.

Therefore, OLMETN-40 supports long-term hypertension management through angiotensin II receptor blockade.

Common Side Effects of OLMETN-40

Some patients may experience side effects while taking olmesartan medoxomil. Possible effects include:

• Dizziness
• Headache
• Fatigue
• Diarrhoea
• Back pain
• Nausea
• Increased blood potassium levels
• Low blood pressure

Most side effects vary between individuals. Moreover, other medicines and existing health conditions can influence how a patient responds to treatment.

Important Safety Information

Use OLMETN-40 only according to the instructions of a qualified healthcare professional.

Blood Pressure and Dizziness

Olmesartan can lower blood pressure. Therefore, some patients may experience dizziness or light-headedness, particularly when treatment starts or when the body has lost too much fluid.

If you experience dizziness, take care when standing up and follow your healthcare professional’s advice.

Kidney Function and Potassium

Olmesartan can affect kidney function and potassium levels in some patients. For this reason, healthcare professionals may monitor kidney function and serum potassium, especially in people with kidney disease, dehydration or other risk factors.

Pregnancy

Do not use OLMETN-40 during pregnancy. Medicines that act directly on the renin-angiotensin system can cause serious fetal injury or death. If pregnancy occurs during treatment, contact your healthcare professional promptly for advice about stopping or changing treatment.

Sprue-Like Enteropathy

Olmesartan can rarely cause a severe, chronic diarrhoea syndrome resembling coeliac disease. If you develop persistent or severe diarrhoea with significant weight loss during treatment, contact your healthcare professional for assessment.

Drug Interactions

Tell your healthcare professional about all prescription medicines, over-the-counter medicines, vitamins and supplements you take.

In particular, discuss:

• Other medicines that lower blood pressure
• Potassium supplements
• Potassium-containing salt substitutes
• Medicines that may affect kidney function
• NSAIDs
• ACE inhibitors
• Aliskiren

Combining medicines that act on the renin-angiotensin system can increase the risk of kidney problems, high potassium and low blood pressure. Therefore, your healthcare professional should review such combinations carefully.

Liver and Kidney Conditions

Tell your doctor if you have kidney disease, liver disease, dehydration or another significant medical condition. Your healthcare professional may monitor your response and laboratory values more closely in these situations.

For detailed prescribing and safety information, refer to the DailyMed Olmesartan Medoxomil prescribing information.

Dosage & Administration

Take OLMETN-40 exactly as prescribed by your healthcare professional.

For adults with hypertension, healthcare professionals may start olmesartan medoxomil at a lower strength and adjust the dose according to the patient’s blood pressure response. The usual adult dose range can extend from 20 mg to 40 mg once daily.

Because the appropriate dose depends on the patient’s condition, kidney function and response to treatment, do not change the dose without medical advice.

You can take OLMETN-40 with or without food. Take the tablet with water and follow the schedule provided by your healthcare professional.

If you miss a dose, follow your doctor’s instructions rather than taking an extra tablet.

Storage

• Store OLMETN-40 in a cool, dry place.
• Protect the tablets from excessive heat and moisture.
• Keep the tablets in their original ALU-ALU packaging until use.
• Protect the product from direct sunlight.
• Keep the medicine out of the sight and reach of children.
• Do not use the tablets after the expiry date printed on the packaging.